Are Sun Pharma.Inds. latest results good or bad?
Sun Pharmaceutical Industries reported a challenging quarter with a 19% decline in Profit After Tax to Rs 2,390.01 crore and a 5.24% drop in net sales. While non-operating income reached a five-quarter high, the overall results indicate concerns about the company's financial health.
Sun Pharmaceutical Industries has reported its financial results for the quarter ending March 2025, highlighting several operational trends. The company's Profit After Tax (PAT) for this quarter is recorded at Rs 2,390.01 crore, which represents a notable decline of 19.0% compared to the average PAT of Rs 2,948.84 crore over the previous four quarters. This trend indicates challenges in maintaining profitability.The Earnings per Share (EPS) has also reached its lowest level in the last five quarters, recorded at Rs 8.96, suggesting a reduction in earnings generated for shareholders, which raises concerns regarding the company's financial health.
In terms of net sales, there was a decline of 5.24% compared to the previous quarter, reflecting a shift from a growth rate of 2.89% in December 2024. The consolidated net profit showed a more pronounced decline of 25.95% compared to the previous quarter's -4.50%.
On a somewhat positive note, Sun Pharma reported its highest non-operating income in the last five quarters, amounting to Rs 612.87 crore. However, this reliance on non-operating income may not be a sustainable long-term strategy.
Overall, the financial results indicate a challenging quarter for Sun Pharmaceutical Industries, and the company saw an adjustment in its evaluation in light of these results.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Sun Pharmaceutical Industries Sees Notable Surge in Derivatives Open Interest Amid Market Volatility
Sun Pharmaceutical Industries Sees Notable Surge in Derivatives Open Interest Amid Market Volatility
Most Read
